ALSUntangled #67: rituximab

References

• Tobinai K, Kobayashi Y, Narabayashi M, Ogura M, Kagami Y, Morishima Y, et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol. 1998;9:527–34.
   PubMed Web of Science ®Google Scholar
• Edwards JCW, Szczepański L, Szechiński J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572–81.
   PubMed Web of Science ®Google Scholar
• Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs 2003;63:803–43.
   PubMed Web of Science ®Google Scholar
• Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12:157–65.
   PubMed Web of Science ®Google Scholar
• Damato V, Evoli A, Iorio R. Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis. JAMA Neurol. 2016;73:1342–8.
   PubMed Web of Science ®Google Scholar
• Hehir MK, Hobson-Webb LD, Benatar M, Barnett C, Silvestri NJ, Howard JF, Jr, et al. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review. Neurology 2017;89:1069–77.
   PubMed Web of Science ®Google Scholar
• Querol L, Rojas-García R, Diaz-Manera J, Barcena J, Pardo J, Ortega-Moreno A, et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm. 2015;2:e149.
   PubMed Web of Science ®Google Scholar
• Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 2011;10:253–63.
   PubMed Web of Science ®Google Scholar
• Komine O, Yamanaka K. Neuroinflammation in motor neuron disease. Nagoya J Med Sci. 2015;77:537–49.
   PubMed Web of Science ®Google Scholar
• Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. 2019;18:211–20.
   PubMed Web of Science ®Google Scholar
• Blüml S, McKeever K, Ettinger R, Smolen J, Herbst R. B-cell targeted therapeutics in clinical development. Arthritis Res Ther. 2013;15 Suppl 1: S4.
   PubMed Web of Science ®Google Scholar
• Hofmann K, Clauder AK, Manz RA. Targeting B Cells and Plasma Cells in Autoimmune Diseases. Front Immunol. 2018;9:835.
   PubMed Web of Science ®Google Scholar
• Khodadadi L, Cheng Q, Radbruch A, Hiepe F. The Maintenance of Memory Plasma Cells. Front Immunol. 2019;10:721.
   PubMed Web of Science ®Google Scholar
• Niebroj-Dobosz I, Jamrozik Z, Janik P, Hausmanowa-Petrusewicz I, Kwieciński H. Anti-neural antibodies in serum and cerebrospinal fluid of amyotrophic lateral sclerosis (ALS) patients. Acta Neurol Scand. 1999;100:238–43.
   PubMed Web of Science ®Google Scholar
• Nielsen A, Folke J, Owczarek S, Svenstrup K, Winge K, Pakkenberg B, et. al. TDP-43 specific autoantibody deline in patients with amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021;8:e937.
   PubMed Web of Science ®Google Scholar
• Naor S, Keren Z, Bronshtein T, Goren E, Machluf M, Melamed D. Development of ALS-like disease in SOD-1 mice deficient of B lymphocytes. J Neurol. 2009;256:1228–35.
   PubMed Web of Science ®Google Scholar
• Tada S, Yasui T, Nakatsuji Y, Okuno T, Koda T, Mochizuki H, et. al. BAFF controls neural cell survival through BAFF receptor. PLoS One. 2013;8:e70924.
   PubMed Web of Science ®Google Scholar
• Pennati A, Asress S, Glass J, Galipeau J. Adoptive transfer of IL-10+ regulatory B cells decreases myeloid macrophages in the central nervous system in a transgenic amyotrophic lateral sclerosis model. Cell Mol Immunol. 2018;15:727–30.
   PubMed Web of Science ®Google Scholar
• Brioschi S, Wang WL, Peng V, Wang M, Shchukina I, Greenberg ZJ, et al. Heterogeneity of meningeal B cells reveals a lymphopoietic niche at the CNS borders. Science 2021;373: eabf9277.
   PubMed Web of Science ®Google Scholar
• Cohen M, Giladi A, Raposo C, Zada M, Li B, Ruckh J, et. al. Meningeal lymphoid structures are activated under acute and chronic spinal cord pathologies. Life Sci Alliance. 2021;4:e202000907.
   PubMed Web of Science ®Google Scholar
• Fouda GE, Bavbek S. Rituximab Hypersensitivity: From Clinical Presentation to Management. Front Pharmacol. 2020;11:572863.
   PubMed Web of Science ®Google Scholar
• Polito V, Barbacki A, Isabwe G. Type I allergic reaction to rituximab upon first lifetime exposure: a case report. Allergy Asthma Clin Immunol. 2020;16:56.
   PubMed Web of Science ®Google Scholar
• Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol. 2014;11:209–19.
   PubMed Web of Science ®Google Scholar
• Sagnelli E, Pisaturo M, Sagnelli C, Coppola N. Rituximab-Based Treatment, HCV Replication, and Hepatic Flares. Clin Dev Immunol. 2012;2012:945950.
   PubMedGoogle Scholar
• Reitblat T, Wechsler A, Reitblat O. Rituximab-related late-onset neutropenia in patients with rheumatic diseases: successful re-challenge of the treatment. Am J Case Rep. 2015;16:211–4.
   PubMedGoogle Scholar
• Mealy MA, Levy M. Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab. J Neuroimmunol. 2015;287:29–30.
   PubMed Web of Science ®Google Scholar
• Barmettler S, Ong M-S, Farmer JR, Choi H, Walter J. Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia. JAMA Netw Open. 2018;1:e184169–e.
   PubMed Web of Science ®Google Scholar
• Focosi D, Tuccori M, Maggi F. Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: What do we know after 20 years of rituximab. Rev Med Virol. 2019;29:e2077.
   PubMed Web of Science ®Google Scholar
• Kosmidis ML, Dalakas MC. Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord. 2010;3:93–105.
   PubMedGoogle Scholar
• Memon AB, Javed A, Caon C, Srivastawa S, Bao F, Bernitsas E, et al. Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. PLoS One. 2018;13:e0190425.
   PubMed Web of Science ®Google Scholar
• Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008;65:1443–8.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Keystone EC, Emery P, Breedveld FC, Betteridge N, Burmester GR, Working Group on the Rituximab Consensus Statement, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:143–50.
   PubMed Web of Science ®Google Scholar
• Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221–32.
   PubMed Web of Science ®Google Scholar
• Tieu J, Smith R, Basu N, Brogan P, D'Cruz D, Dhaun N, et al. Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. Rheumatology (Oxford). 2020;59:e24–e32.
   PubMed Web of Science ®Google Scholar
• Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011;76:1310–5.
   PubMed Web of Science ®Google Scholar